Recent advances in genomic profiling technology have led to the identification of several rare actionable alterations in advanced NSCLC; targeted therapies for many of these molecular NSCLC subtypes are now available. In this episode, the experts evaluate the latest updates from clinical trials using these agents and the impact on clinical practice.
Recent advances in genomic profiling technology have led to the identification of several rare actionable alterations in advanced NSCLC; targeted therapies for many of these molecular NSCLC subtypes are now available. In this episode, the experts evaluate the latest updates from clinical trials using these agents and the impact on clinical practice.